BiotechTube
Ablative Solutions

Ablative Solutions

Kalamazoo, United States· Est.
ablativesolutions.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $80M

Overview

Ablative Solutions is pioneering a catheter-based renal denervation (RDN) system designed to treat patients with uncontrolled hypertension. Its Peregrine System Infusion Catheter utilizes a micro-infusion of dehydrated ethanol to precisely target the renal nerves, offering a potential alternative to lifelong medication. The company is currently conducting clinical trials to demonstrate the safety and efficacy of its approach. As a private entity, Ablative Solutions operates in the competitive but high-potential interventional cardiology and hypertension management market.

CardiovascularHypertension

Technology Platform

Peregrine System Kit: A catheter-based renal denervation system using transvascular micro-infusion of dehydrated ethanol for chemical ablation of renal nerves.

Funding History

3
Total raised:$80M
Series C$40M
Series B$25M
Series A$15M

Opportunities

The Peregrine System targets the large and growing population of patients with uncontrolled hypertension, a multi-billion dollar market with significant unmet need.
Positive data from its pivotal trial could position it as a leading differentiated technology in the renal denervation space.
Success in hypertension could also pave the way for exploring renal denervation in related conditions like heart failure and chronic kidney disease.

Risk Factors

The company faces high clinical risk, as failure of its pivotal TARGET BP III trial to meet endpoints would be catastrophic.
It operates in a competitive landscape with other advanced renal denervation devices and must navigate complex regulatory pathways and future reimbursement challenges.
As a pre-revenue company, it is dependent on external financing to reach commercialization.

Competitive Landscape

Ablative Solutions competes in the renal denervation device market against companies like Medtronic (Symplicity Spyral RF system), ReCor Medical (Paradise ultrasound system, now part of Otsuka), and other private entrants. The competitive landscape is intense, with several systems already holding CE Mark and undergoing U.S. pivotal trials. Differentiation is based on ablation mechanism (chemical vs. thermal), safety profile, and procedural efficacy.

More companies in Digital Health & Biotech SaaS →More companies in United States →